PTC THERAPEUTICS, INC.

PTCT - CIK 0001070081

Market cap$6.03 B

Rank#1263

SEC filings1,262

PTC THERAPEUTICS, INC. trades as PTCT and has a market capitalization of $6.03 B, making it the #1263 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.73B, up 114.5% from the prior year and net income of $683.00M. This page tracks PTC THERAPEUTICS, INC. through 1,262 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.73BFY 2025

Net income (latest FY)$683.00MFY 2025

Operating cash flow (latest FY)$711.20MFY 2025

Total assets (latest FY)$2.90BFY 2025

Net margin39.5%latest FY

Financial performance

Over the last 9 fiscal years PTC THERAPEUTICS, INC.'s revenue grew from $82.70M to $1.73B, a compound annual growth rate of 40.2%. Net profit margin expanded from -171.8% to 39.5% over the same period - every figure below comes from the company's audited annual filings.

PTCT annual revenueView details

Key statistics

Market cap: $6.03 B
Share price (derived)market cap / shares outstanding: $726.95
P/E ratio (trailing FY): 8.8
EPS (diluted)FY 2025: $7.78
Shares outstandingas of 2026-05-05: 0.01B
Long-term debtas of 2025-06-30: $286.01M
Cash & equivalentsas of 2026-03-31: $833.99M
Current ratioas of 2026-03-31: 2.44

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-19
Insider sale notice	144	2026-05-15
Insider trade	4	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
Insider sale notice	144	2026-05-14
Insider sale notice	144	2026-05-14
Insider trade	4	2026-05-12
Insider sale notice	144	2026-05-08

Browse the full filing history (1,262 filings)

Recent press releases

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results2026-05-07
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | PTC Therapeutics.
PTC Therapeutics to Participate in Upcoming Investor Conferences2026-05-04
PTC Therapeutics to Participate in Upcoming Investor Conferences | PTC Therapeutics.
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam2026-04-28
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam | PTC Therapeutics.
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study2026-04-28
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study | PTC Therapeutics.
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 20262026-04-22
Aromatic l-amino acid decarboxylase (AADC) deficiency

Similar companies

The largest companies sharing PTC THERAPEUTICS, INC.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T PTCT vs LLY

JNJJohnson & Johnson$573.98 B PTCT vs JNJ

ABBVAbbVie Inc.$399.47 B PTCT vs ABBV

MRKMerck & Co., Inc.$293.16 B PTCT vs MRK

AZNAstraZeneca PLC$286.27 B PTCT vs AZN

Frequently asked questions

What is PTC THERAPEUTICS, INC.'s market cap?

PTC THERAPEUTICS, INC. (PTCT) has a market capitalization of $6.03 B as of 2026-05-29, ranking #1263 among US-listed companies.

How much revenue does PTC THERAPEUTICS, INC. make?

PTC THERAPEUTICS, INC. reported revenue of $1.73B for fiscal year 2025, an increase of 114.5% year over year.

Is PTC THERAPEUTICS, INC. profitable?

Yes. PTC THERAPEUTICS, INC. reported net income of $683.00M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.